Positive News SentimentPositive NewsNASDAQ:NCEL NLS Pharmaceutics (NCEL) Stock Price, News & Analysis $3.15 -0.01 (-0.32%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About NLS Pharmaceutics Stock (NASDAQ:NCEL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NLS Pharmaceutics alerts:Sign Up Key Stats Today's Range$3.01▼$3.2850-Day Range$1.88▼$4.9152-Week Range$1.83▼$30.80Volume22,759 shsAverage Volume79,250 shsMarket Capitalization$16.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period. The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia. Its lead candidate has advanced into mid-stage clinical trials, where the company is evaluating safety, tolerability and efficacy in patients experiencing severe disruptions in their sleep-wake patterns. Preclinical programs are also exploring additional indications in related neurophysiological and metabolic conditions. Founded in 2015, NLS Pharmaceutics has built a research platform that integrates advanced pharmacokinetic modeling with circadian biology to enhance therapeutic outcomes. The company collaborates with academic institutions and sleep-medicine centers in North America and Europe to support patient recruitment and biomarker development. Through these partnerships, NLS Pharmaceutics aims to accelerate proof-of-concept studies and bring innovative treatments to market more efficiently. NLS Pharmaceutics is led by an executive team with extensive experience in drug discovery, clinical development and regulatory affairs. The company’s strategy centers on addressing underserved patient populations and leveraging its circadian platform to expand into new therapeutic areas. By focusing on precise modulation of biological rhythms, NLS Pharmaceutics seeks to deliver differentiated therapies that improve quality of life for patients with chronic sleep and circadian disorders. AI Generated. May Contain Errors. Read More NLS Pharmaceutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreNCEL MarketRank™: NLS Pharmaceutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 763rd out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingNLS Pharmaceutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNLS Pharmaceutics has received no research coverage in the past 90 days.Read more about NLS Pharmaceutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioNLS Pharmaceutics has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.11% of the float of NLS Pharmaceutics has been sold short.Short Interest Ratio / Days to CoverNLS Pharmaceutics has a short interest ratio ("days to cover") of 1.82, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NLS Pharmaceutics has recently decreased by 10.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNLS Pharmaceutics does not currently pay a dividend.Dividend GrowthNLS Pharmaceutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News SentimentN/A News SentimentNLS Pharmaceutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies. Company Ownership4.2 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of NLS Pharmaceutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $374,998.00 in company stock, which represents 2.1836% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, NLS Pharmaceutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $374,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsNLS Pharmaceutics has minimal institutional ownership at this time.Read more about NLS Pharmaceutics' insider trading history. Receive NCEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NLS Pharmaceutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NCEL Stock News HeadlinesNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesMay 27, 2026 | globenewswire.comNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026April 30, 2026 | globenewswire.comElon’s big June 12 announcementJune 12 is the reported deadline for a major announcement tied to Elon Musk's so-called 'Project Unlimited' - and one under-the-radar tech firm may be at the center of it all. This company has already shipped 5 billion critical components to SpaceX. Because SpaceX has remained private, the partnership has gone almost entirely unnoticed - but that changes the moment the $1.75 trillion IPO goes public and analysts start digging into the supply chain.June 4 at 1:00 AM | Weiss Ratings (Ad)NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceApril 20, 2026 | globenewswire.comNewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium PricingApril 1, 2026 | globenewswire.comNewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 DiabetesMarch 9, 2026 | prnewswire.comNewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization StrategyFebruary 12, 2026 | prnewswire.comNewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering ConferencesJanuary 29, 2026 | prnewswire.comSee More Headlines NCEL Stock Analysis - Frequently Asked Questions How have NCEL shares performed this year? NLS Pharmaceutics' stock was trading at $1.90 at the beginning of 2026. Since then, NCEL stock has increased by 68.9% and is now trading at $3.21. When did NLS Pharmaceutics' stock split? NLS Pharmaceutics shares reverse split on Friday, October 31st 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, October 30th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of NLS Pharmaceutics? Shares of NCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 NCEL's financial health is in the Green zone, according to TradeSmith. NCEL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NCEL Previous SymbolNASDAQ:NLSP CIK1783036 Webwww.nlspharma.com Phone41-44-512-2150Fax41-41-618-8009Employees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.76 Quick Ratio0.76 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.59 per share Price / Book1.98Miscellaneous Outstanding Shares5,350,000Free Float4,468,000Market Cap$16.85 million OptionableNot Optionable Beta0.94 10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free Report This page (NASDAQ:NCEL) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersElon’s big June 12 announcementJune 12 is the reported deadline for a major announcement tied to Elon Musk's so-called 'Project Unlimited' - ...Weiss Ratings | SponsoredA New Approach to Affordable Housing75% of U.S. households cannot afford a median-priced new home. BOXABL's factory-built, foldable homes are desi...BOXABL | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredYour $29.97 book is free todayBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredWhere did Vanguard quietly put $101 billion?Tech investor George Gilder spent 40 years identifying paradigm shifts before they went mainstream - flagging ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NLS Pharmaceutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NLS Pharmaceutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
